Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics (Nasdaq: BBNX) plans to release its Q2 2026 financial results after market close on Wednesday, July 29, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) plans to release its Q2 2026 financial results after market close on Wednesday, July 29, 2026. Management will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to review quarterly performance.
Details
News Market Reaction – BBNX
On Jul 1, the day this news came out, BBNX closed 6.57% above the previous close.
Data tracked by StockTitan Argus for the Jul 1 session.
Key Figures
- Quarter reported
- Q2 2026
- Results to be released after market close
- Earnings release date
- July 29, 2026
- Scheduled after financial markets close
- Conference call time
- 4:30 pm ET
- Management call to review Q2 2026 performance
- Conference call time
- 1:30 pm PT
- Pacific Time equivalent for Q2 2026 call
Previous Earnings date Reports
-
Notice of upcoming Q1 2026 results and conference call timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s second quarter 2026 performance.
The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BI3bd9f03fbd0f42bcb9f566c242240033.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.